Advertisement
Mr. Cole is a founding partner with Spray Venture Partners, a venturecapital firm that focuses exclusively on emerging healthcare technologycompanies. He brings twenty years of medical device operational experience,having served on the boards of 10 companies, two of which he started. Prior tojoining Spray, Mr. Cole served as senior vice president and group president ofBoston Scientific Corporation's (BSC) vascular business, a $1.2 billion group,and was also responsible for BSC's international operations. Prior to BSC, hewas president and chief iperating officer of SCIMED Life Systems before thecompany's merger with Boston Scientific. He also held a variety of executiveand general management positions at Baxter Healthcare. He currently serves onthe Board of Directors of Acorn Cardiovascular, Tryton Medical, Direct FlowMedical, and Tremont Medical, and is actively involved in Kolis Scientific,PneumRx, and Thoratec Laboratories.
Advertisement
"We are thrilled to have Dan Cole as our new Chairman of the Board forOmniSonics," said Richard Ganz, president and CEO, OmniSonics MedicalTechnologies. "Over the last few years, we have been actively building aworld-class team with in-depth experience in product development andcommercialization. Dan's experience and leadership will be a major asset as welaunch our products for vascular occlusive disease and build a word-classcommercial enterprise."
"This is an exciting time to join the OmniSonics team," said J. DanielCole, Chairman of the Board and partner at Spray Venture Partners. "Thecompany has assembled a management team with over 80 cumulative years ofexperience in medical devices and commercial operations. They have developedbreakthrough technology for treating vascular occlusive disease - technologythat has the chance to have a major impact on a serious health issue. Thecompany is ready for the transition from R&D to commercialization, and I'mlooking forward to being a part of that transition."
About OmniSonics Medical Technologies, Inc.
OmniSonics Medical Technologies, Inc., based in Wilmington, MA, is aventure-backed medical device company focused on developing breakthroughproducts for the treatment of vascular occlusive disease. The Company plans tointroduce products based on its patented OmniWave(TM) Technology, the firsttechnology capable of delivering low-power acoustic energy around the activelength of a small diameter wire in a diseased blood vessel. OmniWaveTechnology is designed to have broad applications in vascular occlusiveconditions. Clearance for use in peripheral vascular disease is expected in2007. Additional clinical trials are planned for other indications.
Contact: Judith Rossi978-657-9980 X502 [email protected]
SOURCE OmniSonics Medical Technologies, Inc.
